D. Boral Capital Reiterates “Buy” Rating for Coya Therapeutics (NASDAQ:COYA)

Coya Therapeutics (NASDAQ:COYA)‘s stock had its “buy” rating restated by stock analysts at D. Boral Capital in a note issued to investors on Tuesday,Benzinga reports. They currently have a $15.00 price target on the stock. D. Boral Capital’s price objective suggests a potential upside of 171.94% from the company’s current price.

Other equities analysts have also issued reports about the company. Wall Street Zen raised Coya Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. BTIG Research increased their price target on Coya Therapeutics from $15.00 to $16.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Chardan Capital reissued a “buy” rating and set a $14.00 price target on shares of Coya Therapeutics in a report on Friday, November 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Coya Therapeutics in a research note on Wednesday, October 8th. Finally, Lake Street Capital reiterated a “buy” rating and issued a $17.00 target price on shares of Coya Therapeutics in a research report on Wednesday, November 5th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Coya Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $16.00.

Coya Therapeutics Stock Performance

Shares of COYA opened at $5.52 on Tuesday. Coya Therapeutics has a 1 year low of $4.65 and a 1 year high of $8.29. The company has a market cap of $115.39 million, a price-to-earnings ratio of -4.97 and a beta of 0.20. The firm has a fifty day moving average of $6.07 and a 200-day moving average of $6.06.

Coya Therapeutics (NASDAQ:COYA) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.12). The firm had revenue of $3.56 million during the quarter, compared to analyst estimates of $3.70 million. Coya Therapeutics had a negative return on equity of 55.76% and a negative net margin of 462.24%. Analysts predict that Coya Therapeutics will post -1.15 EPS for the current year.

Institutional Investors Weigh In On Coya Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of COYA. Lantern Wealth Advisors LLC bought a new position in shares of Coya Therapeutics during the 3rd quarter valued at about $66,000. Prosperity Wealth Management Inc. boosted its holdings in Coya Therapeutics by 16.4% during the third quarter. Prosperity Wealth Management Inc. now owns 23,800 shares of the company’s stock worth $136,000 after buying an additional 3,350 shares in the last quarter. Citadel Advisors LLC boosted its holdings in Coya Therapeutics by 51.3% during the third quarter. Citadel Advisors LLC now owns 65,240 shares of the company’s stock worth $372,000 after buying an additional 22,120 shares in the last quarter. Dauntless Investment Group LLC grew its position in Coya Therapeutics by 199.5% in the third quarter. Dauntless Investment Group LLC now owns 153,021 shares of the company’s stock worth $872,000 after buying an additional 101,932 shares during the last quarter. Finally, CM Management LLC increased its holdings in shares of Coya Therapeutics by 50.0% in the third quarter. CM Management LLC now owns 300,000 shares of the company’s stock valued at $1,710,000 after buying an additional 100,000 shares in the last quarter. 39.75% of the stock is owned by institutional investors and hedge funds.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.